{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:58Z","timestamp":1793826058486,"version":"4.6.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar","award":["G03\/181"],"award-info":[{"award-number":["G03\/181"]}]},{"name":"FIS","award":["PI12\/01289"],"award-info":[{"award-number":["PI12\/01289"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","award":["08-2008"],"award-info":[{"award-number":["08-2008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centro Nacional de Investigaci\u00f3n Cardiovascular"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Familial hypercholesterolaemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD). Aortic valve stenosis (AVS) is the most prevalent valvular heart disease and low-density lipoprotein cholesterol (LDL-C) and Lp(a) may be involved in its pathobiology. We investigated the frequency and predictors of severe AVS requiring aortic valve replacement (AVR) in molecularly defined patients with FH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>SAFEHEART is a long-term prospective cohort study of a population with FH and non-affected relatives (NAR). We analysed the frequency and predictors of the need for AVR due to AVS in this cohort. Five thousand and twenty-two subjects were enrolled (3712 with FH; 1310 NAR). Fifty patients with FH (1.48%) and 3 NAR (0.27%) required AVR [odds ratio 5.71; 95% confidence interval (CI): 1.78\u201318.4; P\u2009=\u20090.003] after a mean follow-up of 7.48 (3.75) years. The incidence of AVR was significantly higher in patients with FH (log-rank 5.93; P\u2009=\u20090.015). Cox regression analysis demonstrated an association between FH and AVR (hazard ratio: 3.89; 95% CI: 1.20\u201312.63; P\u2009=\u20090.024), with older age, previous ASCVD, hypertension, increased LDL-CLp(a)-years, and elevated Lp(a) being independently predictive of an event.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The need for AVR due to AVS is significantly increased in FH patients, particularly in those who are older and have previous ASCVD, hypertension, increased LDL-CLp(a)-years and elevated Lp(a). Reduction in LDL-C and Lp(a) together with control of hypertension could retard the progression of AVS in FH, but this needs testing in clinical trials.<\/jats:p>\n                  <jats:p>ClinicalTrials.gov number NCT02693548.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaa1066","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T20:14:04Z","timestamp":1608063244000},"page":"2201-2211","source":"Crossref","is-referenced-by-count":46,"title":["Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia"],"prefix":"10.1093","volume":"42","author":[{"given":"Leopoldo","family":"P\u00e9rez de Isla","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico San Carlos, IDISSC, Facultad de Medicina, Universidad Complutense , C\/Profesor Mart\u00edn Lagos s\/n, 28040 Madrid, Spain"},{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia , Perth, Western Australia, Australia"},{"name":"Lipid Disorders Clinic, Cardiometabolic Services, Department of Cardiology, Royal Perth Hospital , Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8119-1245","authenticated-orcid":false,"given":"Rodrigo","family":"Alonso","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar , Madrid, Spain"},{"name":"Center for Advanced Metabolic Medicine and Nutrition , Santiago de Chile, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edaz-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Abente y Lago , A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Mu\u00f1iz-Grijalvo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Virgen del Roc\u00edo , Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zamb\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Clinic , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Lipids and Atherosclerosis Unit, CIBERObn, IMIBIC\/Reina Sofia University Hospital\/University of Cordoba , Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimundo","family":"de Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Padr\u00f3","sequence":"additional","affiliation":[{"name":"Programa-ICCC Cardiovascular, Institut de Recerca del Hospital Santa Creu i Sant Pau, IIB Santa Pau , Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Miranda","sequence":"additional","affiliation":[{"name":"Lipids and Atherosclerosis Unit, CIBERObn, IMIBIC\/Reina Sofia University Hospital\/University of Cordoba , Cordoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mata","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Hipercolesterolemia Familiar , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"2022102514354121100_ehaa1066-B1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2022102514354121100_ehaa1066-B2","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102514354121100_ehaa1066-B3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.mayocp.2018.01.020","article-title":"Management of patients with aortic valve stenosis","volume":"93","author":"Kanwar","year":"2018","journal-title":"Mayo Clin. Proc"},{"key":"2022102514354121100_ehaa1066-B4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2022102514354121100_ehaa1066-B5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamacardio.2019.3903","article-title":"Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia","volume":"4","author":"Mundal","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102514354121100_ehaa1066-B6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B7","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/j.jacc.2015.09.087","article-title":"Increased aortic valve calcification in familial hypercholesterolemia prevalence, extent, and associated risk factors","volume":"66","author":"Ten Kate","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B8","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1001\/jama.2014.13959","article-title":"Association of low-density lipoprotein cholesterol\u2014related genetic variants with aortic valve calcium and incident aortic stenosis","volume":"312","author":"Smith","year":"2014","journal-title":"JAMA"},{"key":"2022102514354121100_ehaa1066-B9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J Intern Med"},{"key":"2022102514354121100_ehaa1066-B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2018.11.040","article-title":"Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia","volume":"281","author":"Vuorio","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022102514354121100_ehaa1066-B12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/biom9120760","article-title":"Lipoprotein(A) as orchestrator of calcific aortic valve stenosis","volume":"9","author":"Schnitzler","year":"2019","journal-title":"Biomolecules"},{"key":"2022102514354121100_ehaa1066-B13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B14","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: n important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B16","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: Insights from the SAFEHEART registry (Spanish familial hypercholesterolaemia cohort study","volume":"36","author":"De Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102514354121100_ehaa1066-B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514354121100_ehaa1066-B18","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022102514354121100_ehaa1066-B19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0002-9149(97)89309-5","article-title":"Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia","volume":"77","author":"Schmidt","year":"1996","journal-title":"Am J Cardiol"},{"key":"2022102514354121100_ehaa1066-B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102514354121100_ehaa1066-B21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2017.04.002","article-title":"Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: the SAFEHEART registry","volume":"262","author":"Bourbon","year":"2017","journal-title":"Atherosclerosis"},{"key":"2022102514354121100_ehaa1066-B22","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: The SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study","volume":"135","author":"P\u00e9rez De Isla","year":"2017","journal-title":"Circulation"},{"key":"2022102514354121100_ehaa1066-B23","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.recesp.2019.10.013","article-title":"Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry","volume":"73","author":"P\u00e9rez de Isla","year":"2020","journal-title":"Rev Esp Cardiol"},{"key":"2022102514354121100_ehaa1066-B25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B26","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514354121100_ehaa1066-B27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (Astronomer) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"2022102514354121100_ehaa1066-B28","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102514354121100_ehaa1066-B29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102514354121100_ehaa1066-B30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102514354121100_ehaa1066-B31","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jacc.2018.12.036","article-title":"In search of patients with elevated Lp(a): seek and ye shall find","volume":"73","author":"Tsimikas","year":"2019","journal-title":"J. Am. Coll. Cardiol"},{"key":"2022102514354121100_ehaa1066-B32","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2022102514354121100_ehaa1066-B33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/22\/2201\/46625962\/ehaa1066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/22\/2201\/46625962\/ehaa1066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:23:50Z","timestamp":1666718630000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/22\/2201\/6091158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":33,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1066","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,7]]},"published":{"date-parts":[[2021,1,12]]}}}